CardioVascular BioTherapeutics to Hold Business and Clinical Trial Update Conference Call on November 28.

LAS VEGAS -- CardioVascular BioTherapeutics, Inc. (OTCBB:CVBT) will host a conference call for investors and other interested parties on Wednesday, November 28, 2007 at 11:00 a.m. EST/8:00 a.m. PST to provide a business update and discuss progress on plans for a Phase II clinical trial for the treatment of severe coronary heart disease. Company executives will also conduct a question and answer session following prepared remarks.

The Company's quarterly newsletter, authored by Dr. Thomas J. Stegmann, CVBT Co-Founder, Co-President and Chief Medical Officer, will be distributed to all investors prior to the call. The newsletter provides a summary of clinical trial progress for medical indications including severe Coronary Heart Disease, dermal wound healing, Peripheral Arterial Disease, and disc ischemia. The Company's steadfast belief in the future promise of angiogenesis therapy as a viable treatment option is also addressed.

Individuals interested in listening to the conference call may do so by dialing [phone] for domestic callers or [phone] for international callers. A telephone replay will be available for 48 hours following the conclusion of the call by dialing [phone] for domestic callers, or [phone] for international callers, and entering reservation code 24915702.

The live conference call will be accessible via the Internet on the Investor Relations section of the Company's website at www.cvbt.com, along with the accompanying presentation. A recording of the call will also be available for 30 days following the completion of the call. The quarterly newsletter will be available on the homepage of the Company's website following the call.

About CardioVascular BioTherapeutics

CVBT is a biopharmaceutical company developing drug candidates with FGF-1 as its active pharmaceutical ingredient (API) for diseases characterized by inadequate blood flow to a tissue or organ. The company has FDA-authorization for a Phase II trial to treat severe Coronary Heart Disease (CVBT-141H) and a Phase I trial to treat Peripheral Arterial Disease (CVBT-141C). A Phase Ib or Phase II trial to treat dermal wound healing in diabetics (CVBT-141B) is estimated to begin in the first quarter of 2008.